Chai Discovery vs Veeva Systems

Side-by-side comparison of AI visibility scores, market position, and capabilities

Veeva Systems leads in AI visibility (99 vs 69)
Chai Discovery logo

Chai Discovery

ChallengerHealthcare Tech

AI Molecular Discovery

AI molecular discovery unicorn ($1.3B valuation). 100x improvement in de novo antibody design success. Backed by OpenAI. Eli Lilly partnership. Founded 2023, SF. $225M+ raised.

AI VisibilityBeta
Overall Score
B69
Category Rank
#1 of 1
AI Consensus
77%
Trend
up
Per Platform
ChatGPT
74
Perplexity
74
Gemini
73

About

Chai Discovery is an AI-driven molecular discovery company founded in 2024 and headquartered in San Francisco. The company was spun out of research conducted by scientists with backgrounds at leading computational biology and AI organizations, with the founding mission of applying the latest advances in generative AI to accelerate drug discovery — particularly the historically difficult challenge of designing novel antibodies and small molecules from scratch rather than optimizing known chemical scaffolds.\n\nChai's core technology is a foundation model for molecular structure prediction and de novo design that operates across proteins, small molecules, nucleic acids, and their complexes. The company's flagship research achievement is a reported 100-fold improvement in de novo antibody design success rates, enabling the generation of functional antibody candidates without requiring extensive experimental screening campaigns. Chai Discovery has established a research partnership with Eli Lilly, one of the world's largest pharmaceutical companies, to apply its platform to therapeutic target programs. The company is backed by OpenAI, reflecting the deep connection between large-scale AI modeling techniques and the biological sequence-structure-function prediction task.\n\nChai Discovery reached a $1.3 billion valuation within its first year of operation, an exceptionally rapid ascent reflecting the strategic premium investors place on AI-native molecular discovery platforms. The company operates at the intersection of structural biology, generative AI, and therapeutic development, competing with platforms like Isomorphic Labs, Recursion, and Insilico Medicine in the race to demonstrate AI-designed drugs in human clinical trials.

Full profile
Veeva Systems logo

Veeva Systems

LeaderHealthcare Tech

Life Sciences Cloud

Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.

AI VisibilityBeta
Overall Score
A99
Category Rank
#1 of 1
AI Consensus
93%
Trend
up
Per Platform
ChatGPT
99
Perplexity
99
Gemini
99

About

Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.

Full profile

AI Visibility Head-to-Head

69
Overall Score
99
#1
Category Rank
#1
77
AI Consensus
93
up
Trend
up
74
ChatGPT
99
74
Perplexity
99
73
Gemini
99
65
Claude
97
70
Grok
97

Key Details

Category
AI Molecular Discovery
Life Sciences Cloud
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Chai Discovery
AI Molecular Discovery
Only Veeva Systems
Life Sciences Cloud

Integrations

Only Veeva Systems
Veeva Systems is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.